10th week of 2011 patent applcation highlights part 29 |
Patent application number | Title | Published |
20110058999 | LOW TEMPERATURE SELECTIVE CATALYTIC REDUCTION CATALYST AND ASSOCIATED SYSTEMS AND METHODS - According to one embodiment, described herein is an exhaust gas after-treatment system that is coupleable in exhaust gas stream receiving communication with an internal combustion engine. The exhaust gas after-treatment system includes a low temperature SCR catalyst configured to reduce NO | 2011-03-10 |
20110059000 | METHODS OF SEQUESTERING CO2 - Methods of sequestering carbon dioxide (CO | 2011-03-10 |
20110059001 | Monetizing Remote Gas Using High Energy Materials - The present application is directed to a method and system for monetizing energy. More specifically, the invention is directed to the economically efficient utilization of remote or stranded natural gas resources. The invention includes importing a high energy density material into an energy market and distributing the high energy density material (HEDM) therein. The HEDM is produced from reduction of a material oxide such as boria into the HEDM, which may be boron. The reduction utilizes remote hydrocarbon resources such as stranded natural gas resources. | 2011-03-10 |
20110059002 | METHODS AND APPARATUS FOR RECOVERY OF SILICON AND SILICON CARBIDE FROM SPENT WAFER-SAWING SLURRY - Methods, systems, and apparatus are disclosed herein for recovery of high-purity silicon, silicon carbide and PEG from a slurry produced during a wafer cutting process. A silicon-containing material can be processed for production of a silicon-rich composition. Silicon carbide and PEG recovered from the silicon-containing material can be used to form a wafer-saw cutting fluid. The silicon-rich composition can be reacted with iodine containing compounds that can be purified and/or used to form deposited silicon of high purity. The produced silicon can be used in the photovoltaic industry or semiconductor industry. | 2011-03-10 |
20110059003 | METHODS OF GROWING A SILICON CARBIDE EPITAXIAL LAYER ON A SUBSTRATE TO INCREASE AND CONTROL CARRIER LIFETIME - A method of growing an epitaxial layer on a substrate is generally provided. According to the method, the substrate is heated in a chemical vapor deposition chamber to a growth temperature in the presence of a carbon source gas, then the epitaxial layer is grown on the substrate at the growth temperature, and finally the substrate is cooled in a chemical vapor deposition chamber to at least about 80% of the growth temperature in the presence of a carbon source gas. Substrates formed from this method can have a carrier lifetime between about 0.25 μs and about 9.9 μs. | 2011-03-10 |
20110059004 | System and Method for Controlling the System for the Production of Polycrystalline Silicon - A system and a method for the production of polycrystalline silicon according to the monosilane process are disclosed. At least one reactor ( | 2011-03-10 |
20110059005 | Iron nitride powders for use in magnetic, electromagnetic, and microelectronic devices - A method of making iron nitride powder is provided. The method comprises the steps of: a) providing an iron-based starting material; b) reducing the starting material by heating the starting material in a fluidized bed reactor in the presence of a reducing agent; c) nitriding the material obtained from step (b) by contacting the material with a nitrogen source. Also provided is the iron nitride powder made by the above method. | 2011-03-10 |
20110059006 | Methods for Production of Carbon Nanomaterials in the Presence of a Carbon Black Catalyst - A method and apparatus for production of nanoscale materials is disclosed. In the preferred embodiments, the invention is scalable and tunable to reliably produce nanoscale materials of specifically desired qualities and at relatively high levels of purity. In a preferred embodiment, combustible gas is discharged onto a substrate through a multi-zone flame facilitating the formation of nanoscale materials such as single and multi-wall nanotubes. | 2011-03-10 |
20110059007 | Lithium niobate SAW wafer containing Ta impurities - The low Ta impurity content in pyrochlore ore makes it unnecessary to use a solvent extraction process to separate Nb from Ta. Consequently, niobium pentoxide powders using this ore can be produced at lower cost than competing mining/refining approaches, but in turn contain significant amounts of Ta impurities. SAW wafers are grown from melts produced by reacting niobium pentoxide powders containing Ta impurities at levels of 200 ppm or more by weight. Given proper amounts of starting powders, crystals can be grown with good yields and reproducible properties that satisfy typical SAW wafer specifications. The consistency across various lots of powders may be further improved by adding an appropriate amount of Ta pentoxide to the starting powders. | 2011-03-10 |
20110059008 | Regenerating Method for Activated Alumina Used in Regenerating Working Fluid of Hydrogen Peroxide - A regenerating method for activated alumina used in regenerating working fluid of hydrogen peroxide comprises the following steps: adding deactivated alumina discharged from a regenerating bed for working fluid of hydrogen peroxide with fire resistant alumina into a reactor through the top of the reactor and settling by gravity, oxidizing atmosphere entering into the reactor from the bottom of the reactor and running upwardly, discharging regenerated alumina and fire resistant alumina through the discharging device on the bottom of the reactor, discharging exit gas through the discharge port on the top of the reactor, the reaction temperature ranging from 360-800° C., the residence time of solid feed in the reactor ranging from 3-15 h. The method is economic, environment-protective, safe, and low-costly. The regenerated alumina will not poison palladium catalyst. | 2011-03-10 |
20110059009 | Thermochemical Hydrogen Produced From A Vanadium Decomposition Cycle - A thermochemical water-splitting process all reactions of which operate at relatively low temperatures and high efficiencies, and in which relatively inexpensive materials and processing methods are made possible. This invention involves the decomposition of a metal halide compound, i.e., one which is capable of being reduced from a higher oxidation state to lower oxidation state, e.g. vanadium chloride III→vanadium dichloride. The process is cyclic and regenerative, and the only net inputs are water and heat; and the only net outputs are hydrogen and oxygen. The process makes it possible to utilize a wide variety of available heat, including solar, sources for the energy input. | 2011-03-10 |
20110059010 | DUAL PHASE DRUG RELEASE SYSTEM - The present invention relates to conjugate comprising a carrier substituted with one or more occurrences of a moiety having the structure (I): wherein each occurrence of M is independently a modifier having a molecular weight ≦10 kDa; denotes direct of indirect attachment of M to linker L | 2011-03-10 |
20110059011 | DIAGNOSIS AND TREATMENT OF DISEASED AND DAMAGED TISSUE - The present invention relates to the diagnosis and treatment of leukemia and cardiovascular disease, as well as the detection of diseased and damaged tissue. More particularly, the present invention provides methods for targeting calcitonin receptor expressing cells for the diagnosis and treatment of leukemia or cardiovascular disease, and for stimulating wound healing. The invention also provides antibodies to calcitonin receptor expressing cells and methods of imaging or localising cells expressing calcitonin receptor. Also provided is an enriched population of CTR | 2011-03-10 |
20110059012 | IDENTIFICATION OF CD8+ T CELLS THAT ARE CD161HI AND/OR IL18R (ALPHA) HI AND HAVE RAPID DRUG EFFLUX CAPACITY - This invention provides, among other things, methods for the identification and isolation of viable putative long-lived antigen-specific memory CD8 | 2011-03-10 |
20110059013 | ANTI-ROBO4 ANTIBODIES AND USES THEREFOR - The invention provides anti-Robo4 antibodies, and compositions comprising the antibodies and methods of using these antibodies, including diagnostic and therapeutic methods. | 2011-03-10 |
20110059014 | COMPOUNDS AND METHODS OF MAKING COMPOUNDS - Embodiments of the present disclosure provide for compounds and methods of making compounds such as those shown in FIGS. | 2011-03-10 |
20110059015 | VACCINE - The application relates to antibodies and fragments capable of binding HIV-1 gp120 protein, nucleic acids encoding such proteins, to the use of such proteins to identify active compounds, and to the use of the compounds as vaccines. | 2011-03-10 |
20110059016 | OPTICAL ASSAY SYSTEM WITH A MULTI-PROBE IMAGING ARRAY - The subject matter described herein relates to an optical assay system having a multi-probe imaging array that orients a plurality of probes with respect to one another and to a sample. According to one aspect, the subject matter described herein includes a multi-probe imaging array for contacting biological samples and simultaneously illuminating a plurality of locations on the biological sample and collecting the reflected radiation from the locations. The multi-probe imaging array can be used for the rapid imaging of biological samples, for example, during surgery. | 2011-03-10 |
20110059017 | POLYMER COATED SERS NANOTAG - An encapsulated surface enhanced Raman scattering (SERS) tag. The tag includes a metal core and an encapsulant, typically a glass encapsulant. The encapsulant is further derivatized with a polymer. | 2011-03-10 |
20110059018 | COVALENTLY BINDING IMAGING PROBES - The present invention relates to molecular probes of the formula (I) | 2011-03-10 |
20110059019 | NOVEL ARYL PIPERAZINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE AND SEROTONIN RECEPTORS - This invention provides novel aryl piperazine derivatives having medical utility, in particular as modulators of dopamine and serotonin receptors, preferably the D | 2011-03-10 |
20110059020 | LIPOSOME COMPOSITION, AND DIAGNOSTIC CONTRAST AGENT, THERAPEUTIC ENHANCER, AND PHARMACEUTICAL COMPOSITION USING THE SAME - To provide a liposome composition, which contains at least one liposome; gas entrapped in the liposome, and at least one metal oxide particle encapsulated in or adsorbed on the liposome, wherein the liposome composition satisfies a ratio B/A of 0.01 to 5, where A is a volume of the gas contained in the liposome on the basis of micro liter, and B is a mass of the at least one metal oxide particle contained in the liposome on the basis of milligram. | 2011-03-10 |
20110059021 | PROCESS FOR PREPARING VARIANT OF ERYSIPELOTHRIX RHUSIOPATHIAE SURFACE PROTECTIVE ANTIGEN IN E. COLI - A variant of | 2011-03-10 |
20110059022 | TWO PHOTON TRACER, METHOD FOR THE PREPARATION THEREOF AND THE USE THEREOF IN SCREENING ANTICANCER AGENTS - Disclosed herein are compounds useful as two-photon tracers. Also, methods are provided for visualizing intracellular glucose uptake, screening anticancer agents, and diagnosing cancer using the compounds. They exhibit preferential uptake by cancer cells, penetrability sufficient to allow bright section images, high water solubility, high pH resistance and low toxicity in addition to applicability to living cells in deep tissues over a long period of time. | 2011-03-10 |
20110059023 | NARROWBAND IMAGING USING NEAR-INFRARED ABSORBING NANOPARTICLES - Devices and methods are provided for image identification of contrast agents comprising nanopartiles. The imaging devices and methods may also be configured to identify target tissues from surrounding tissues such as disease conditions (e.g. cancer tumors) through narrow-band imaging of tissue. Contrast agents such as near-infrared absorbing nanoparticles may be introduced to an organism to distinguish target cells, tissues, or structures from normal tissue. The contrast agent is allowed to preferentially accumulate in the target cells, tissues or structures. As the contrast agents are adapted to preferentially absorb one or more wavelengths of light, the reflection of one wavelength or band of wavelengths by the contrast agents is compared to a separate wavelength or band of wavelengths to identify the target cells, tissues, or structures. In this way, the comparisons identify the presence of the preferential accumulation of the contrast agent in the target cells, tissues or structures. | 2011-03-10 |
20110059024 | LIPOSOME COMPOSITION, AND DIAGNOSTIC CONTRAST AGENT, THERAPEUTIC ENHANCER, AND PHARMACEUTICAL COMPOSITION USING THE SAME - To provide a liposome composition, which contains at least one liposome, gas entrapped in the liposome, and at least one fullerene encapsulated in or adsorbed on the liposome. | 2011-03-10 |
20110059025 | IN VIVO IMAGING - The present invention provides an imaging method for obtaining an image of a patient by means of a contrast agent wherein the method comprises subjecting the patient to an imaging method for which the contrast agent is suitable, wherein the contrast agent comprises: (a) a binding moiety; and (b) a recognition moiety capable of targeting the contrast agent to a site within the body of the patient, and wherein the binding moiety comprises a metal-binding protein, polypeptide or peptide which is bound to or encapsulates a magnetic or magnetizable substance. | 2011-03-10 |
20110059026 | PHARMACEUTICAL DOSAGE FORM BEARING PREGNANCY-FRIENDLY INDICIA - A pharmaceutical dosage form comprising at least one active ingredient and destined for administration to pregnant women. The pharmaceutical dosage form bears pregnancy-friendly indicia apt to improve patient compliance with medically recommended dosage regimen resulting in improved product effectiveness. The pregnancy-friendly indicia is also apt to diminish the incidence of erroneous dispensing of or erroneous ingestion of pharmaceutical dosage forms not intended for pregnant women. Also disclosed is a method for achieving improved patient compliance resulting in improved product effectiveness. Also disclosed is a method for diminishing the incidence of erroneous dispensing of or erroneous ingestion of dosage forms not intended for pregnant women. Said methods comprising providing a pharmaceutical dosage form, intended for use by pregnant women, bearing pregnancy-friendly indicia apt to graphically distinguish dosage forms intended to be used during pregnancy from others. | 2011-03-10 |
20110059027 | Biocidal aldehyde composition - A novel combination of OPA, a surfactant, and alcohol. The surfactant is preferably a dual chain quaternary ammonium compound consisting of a mixture of alkyl dimethyl-benzylammonium chlorides and alkyl dimethylethylbenzylammonium, that absorbs onto a surface and alters the free energy of that surface. The alcohol is preferably isopropyl alcohol. The OPA is the dialdehyde C | 2011-03-10 |
20110059028 | METHOD FOR MEMBRANE ELECTROLYSIS AND THE USE OF THE PRODUCTS OBTAINED BY IT - A metal sulphate is added to the alkali metal chloride solution in membrane electrolysis in order to increase the amount of catholyte solution formed. At the same time, a metal sulphate is added to the anolyte solution in order to improve its stability. | 2011-03-10 |
20110059029 | DUAL COMPONENT ORAL CARE PRODUCT - A dental composition which, e.g., eliminates or substantially reduces the discomfort and pain associated with dentinal hypersensitivity and exhibits enhanced anticaries and remineralization benefits, which composition contains a first component containing a calcium source, a second component containing an anion source and at least one of the components containing a basic amino acid in free or salt form, and the first and second components being maintained separate from each other until dispensed and combined for application to teeth. | 2011-03-10 |
20110059030 | Dental Whitening Compositions - A two-component whitening system has a de-sensitizing effect as well as re-mineralizing capability. The system may be an unfoamed, a foamed or a foamable composition. | 2011-03-10 |
20110059031 | Oral Cereal Beta Glucan Compositions - The present invention relates to oral compositions comprising a β (1-3) β (1-4) glucan and one, or more than one compound of interest. In particular, the present invention provides an oral composition comprising an effective amount of a β (1-3) β (1-4) glucan and an effective amount of one, or more than one of an antibacterial agent, a botanical extract, and a flavouring agent, and also provides a method of using this composition for maintaining fresh breath in a subject over a prolonged period of time. | 2011-03-10 |
20110059032 | Hydrocarbon Mixtures and use Thereof - The invention relates to a hydrocarbon mixture that contains at least two hydrocarbons that are different from each other, the number of carbons thereof differing by more than one, wherein said two hydrocarbons that differ from each other make up at least 60% by weight, preferably at least 70% by weight of the total of the hydrocarbons. The invention also relates to the use of said hydrocarbon mixtures and to cosmetic and/or pharmaceutical preparations containing said hydrocarbon mixtures. | 2011-03-10 |
20110059033 | ULTRAVIOLET ABSORBING COMPOSITION - An object of the invention is to provide an ultraviolet absorbing composition for a skin and hair, which has absorption of high absorbance in both UV-A region and UV-B region, wherein an ultraviolet absorbing compounds in the ultraviolet absorbing composition will not precipitate or turn to yellow in the process of preparing cosmetics. Moreover, the ultraviolet absorbing composition shows excellent feeling in use, and will not dye clothes easily, and may be applied to the skin and hair of a living object, and exhibits excellent capability of absorbing an ultraviolet light. | 2011-03-10 |
20110059034 | ASCORBIC ACID DERIVATIVE OR SALT THEREOF, PRODUCTION METHOD THEREOF, AND COSMETIC - Disclosed is an ascorbic acid derivative or a salt thereof wherein at least one of hydrogen atoms in hydroxy groups at the 2-position and the 3-position of ascorbic acid is substituted by R—O—CH | 2011-03-10 |
20110059035 | COMPOSITIONS BASED ON POLYMER/HYDROGEN PEROXIDE COMPLEXES AND USES THEREOF - The invention relates to a cosmetic assembly for improving the appearance of the skin, comprising a first anhydrous composition comprising a polymer-H | 2011-03-10 |
20110059036 | NITRIC OXIDE-RELEASING POLYMERS - This invention relates to compositions comprising carbon-based diazeniumdiolates attached to hydrophobic polymers that releases nitric oxide (NO). The carbon-based diazeniumdiolated polymers release NO spontaneously under physiological conditions without subsequence nitrosamine formation. The present invention also relates to methods of preparing the carbon-based diazeniumdiolated polymers, compositions comprising such polymers, methods of using such compositions, and devices employing such polymer compositions. | 2011-03-10 |
20110059037 | POLYMERIC COMPOSITIONS CONTAINING IR-EMITTING/ABSORBING ADDITIVES AND SHAPED ARTICLES COMPRISED THEREOF - Polymeric compositions containing additives having properties of emission and/or absorption of radiation in the long infrared region, and articles shaped therefrom are produced, including yarns and textile articles such as fabrics or knits; such additives include organic additives or inorganic fillers which have a capacity for absorption/emission of radiation in the infrared region, in a wavelength range of from 2 μm to 20 μm, and also a polymeric substrate, with the proviso that the inorganic fillers may be selected from among oxides, sulfates, carbonates, phosphates and silicates, and such inorganic fillers having an average particle size of less than 2 μm. | 2011-03-10 |
20110059038 | METHOD OF STABILIZING A POLYSILOXANE EMULSION AND COMPOSITIONS CONTAINING STABILIZED EMULSIONS - A method of stabilizing an emulsion containing a polysiloxane and one or more surfactants comprising adding an effective amount of dispersion containing a DADMAC/acrylamide copolymer and one or more sulfate salts into said emulsion is disclosed. An emulsion/cosmetically acceptable emulsion comprising a polysiloxane, at least one surfactant, and a dispersion containing DADMAC/acrylamide copolymer and one or more sulfate salts is also disclosed. | 2011-03-10 |
20110059039 | USE OF PEO-PBO BLOCK COPOLYMERS IN OPHTHALMIC COMPOSITIONS - The use of poly(oxyethylene)-poly(oxybutylene) block copolymers in pharmaceutical compositions useful for modifying the surfaces of contact lenses and other medical devices is disclosed. The present invention is based in-part on a discovery that this class of compounds is particularly efficient in wetting hydrophobic surfaces, such as the surfaces of silicone hydrogel contact lenses and other types of ophthalmic lenses. Such compounds are also useful for cleaning purposes. The use of the compounds as surfactants in various types of compositions for treating contact lenses therefore represents a preferred embodiment of the present invention. | 2011-03-10 |
20110059040 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL AND BACTERIAL ACTIVITY - Described herein are methods of inhibiting the activity of a virus or a bacterium comprising contacting a virus or bacterium with a polymer functionalized with at least one boronic acid moiety. Also described are methods of treatment using such functionalized polymers. | 2011-03-10 |
20110059041 | Vaccine for treatment and prevention of herpes simplex virus infection - The present invention relates to methods and compositions for the prevention and treatment of herpes virus infections. The invention provides antigenic peptides, and pharmaceutical compositions comprising complexes of antigenic peptides and adjuvants that can activate an immune response against herpes viruses. The invention also provides methods of making the antigenic peptides and complexes of antigenic peptides and adjuvants. Methods of use of the pharmaceutical compositions are also provided. | 2011-03-10 |
20110059042 | SUBSTITUTED IL-15 - The invention provides IL-15 amino acid sequences with amino acid substitutions that reduce or eliminate deamidation of IL-15 and degradation by-products. The invention also provides DNA sequences that encode the substituted amino acid sequences, a pharmaceutical composition comprising the substituted IL-15 amino acid sequence and a pharmaceutically acceptable carrier, and a method of treating a condition in a mammalian host comprising administering to the host the substituted IL-15 amino acid sequence or the pharmaceutical composition including the substituted IL-15 amino acid sequence in an amount effective to treat the condition in the host. | 2011-03-10 |
20110059043 | CHEMICAL COMPOUNDS - The invention concerns benzodiazepine derivatives of Formula I: | 2011-03-10 |
20110059044 | Method of treating pulmonary disease with interferons - A method of treating a pulmonary disease such as, for instance idiophathic pulmonary fibrosis (IPF) and asthma, comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) are provided. | 2011-03-10 |
20110059045 | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT - The invention relates to therapeutic compositions for the treatment of cancer and, more specifically, compositions containing an agonist ligand for receptor 4-1BB and a type-1 interferon, the simultaneous or sequential delivery of which results in a synergic antitumour effect in relation to the individual delivery of any of the components. The invention also relates to the therapeutic uses of the combinations of the invention for the treatment of cancer. The invention further relates to polynucleotides that code for compounds, vectors and cells containing same, as well as to the use thereof for the treatment of cancer. | 2011-03-10 |
20110059046 | DERIVATIVES OF GEFITINIB - This invention relates to novel quinazoline derivatives, their derivatives, pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by inhibiting cell surface tyrosine receptor kinases. | 2011-03-10 |
20110059047 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formulae I, II, III, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 2011-03-10 |
20110059048 | THE FUNGUS FUSARIUM SOLANI STRAIN 'FS-K' AND ITS USE IN THE BIOLOGICAL CONTROL OF PLANT PATHOGENS AND IN THE ENHANCEMENT OF PLANT GROWTH AND PRODUCTIVITY - This invention refers to the pure culture of a wild isolate of the fungal species | 2011-03-10 |
20110059049 | POXVIRAL ONCOLYTIC VECTORS - A poxvirus other than NYVAC but comprising a defective F4L and/or I4L gene and compositions comprising such poxvirus are useful for therapeutic purposes, and more particularly for the treatment of cancer. | 2011-03-10 |
20110059050 | METHODS AND COMPOSITIONS RELATING TO STEM CELL TRANSPLANTATION - The invention relates to methods and compositions for stem cell transplantation. Aspects of the invention relate to administering hematopoietic stem cells and mesemchymal cells to a patient. | 2011-03-10 |
20110059051 | Molecular Control of Brown Fat Differentiation and Engergy Expenditure - The invention provides methods and compositions for inducing brown fat cell differentiation through modulation of Prdm 16 activity or expression. Also provided are methods for preventing or treating obesity or an obesity related disorder in a subject through stimulation of Prdm 16 expression or activity. Further provided are methods for identifying compounds that are capable of modulating Prdm 16 expression or activity. | 2011-03-10 |
20110059052 | CELLULAR THERAPEUTIC AGENT FOR INCONTINENCE OR URINE COMPRISING STEM CELLS ORIGINATED FROM DECIDUA OR ADIPOSE - The present invention relates to a cellular therapeutic agent for treating urinary incontinence, and more particularly to a cellular therapeutic agent for treating urinary incontinence, which contains stem cells derived from the decidua of the placenta or menstrual fluid or stem cells derived from adipose. The decidua-derived stem cells or adipose-derived stem cells show the effects of increasing leak point pressure and urethral sphincter contractility, and thus are useful as an agent for treating urinary incontinence. | 2011-03-10 |
20110059053 | METHOD OF TREATING BIOCELLS - A method of treating biocells includes the steps of: a. providing biocells; b. applying at least one stressor to the biocells sufficient to cause nonlethal and reparable cell wall damage to the biocells, thereby putting the biocells in a catabolic state during which catabolic metabolic functions predominate over anabolic metabolic functions; and c. obtaining at least one product produced by the biocells during the catabolic state. In another embodiment, the method includes the steps of: a. providing biocells that are mammalian cells; b. applying at least one stressor to the biocells sufficient to cause nonlethal and reparable cell wall damage to the biocells, the reparable cell wall damage comprising openings that allow increased passage of materials through the cells walls; and c. inserting foreign DNA through the openings into the biocells. | 2011-03-10 |
20110059054 | ENHANCED DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY - Described herein are methods of cancer immunotherapy, particularly methods of preparing a population of enhanced dendritic cells and methods of treating cancer using the enhanced dendritic cells. | 2011-03-10 |
20110059055 | TREATING MYELIN DISEASES WITH OPTIMIZED CELL PREPARATIONS - The disclosure relates to oligodendrocyte-biased glial progenitor cells and methods of making, isolating, and using such cells. | 2011-03-10 |
20110059056 | Method for the Generation of Genetically Modified Vertebrate Precursor Lymphocytes and Use Thereof for the Production of Heterologous Binding Proteins - The present invention generally relates to the fields of genetic engineering and antibody production. In particular, it relates to the generation of genetically modified vertebrate precursor lymphocytes that have the potential to differentiate into more mature lymphoid lineage cells, and to the use thereof for the production of any heterologous antibody or binding protein. | 2011-03-10 |
20110059057 | KERATINOCYTES EXPRESSING EXOGENOUS ANGIOGENIC GROWTH FACTORS - The present invention relates to in vitro cultured skin tissue, and in particular to cultured skin tissue comprising exogenous genes encoding angiogenic growth factors. In some embodiments, the keratinocytes express exogenous angiopoietin-1, HIF-1α, or a member of the VEGF family, preferably VEGF-A. In particularly preferred embodiments, the keratinocytes are incorporated into cultured skin tissue. | 2011-03-10 |
20110059058 | Strain of Lactobacillus Rhamnosus - The invention relates to a novel strain of | 2011-03-10 |
20110059059 | Methods for Treating Ischemic Tissue - Compositions and methods for treating ischemic tissue are provided herein. | 2011-03-10 |
20110059060 | THURICIN CD, AN ANTIMICROBIAL FOR SPECIFICALLY TARGETING CLOSTRIDIUM DIFFICILE - The present invention relates to a new bacteriocin, to microbial strains which can produce it and to uses of the bacteriocin and the strains. The bacteriocin is effective against | 2011-03-10 |
20110059061 | Bioabsorbable Surgical Composition - Bioabsorbable macromer compositions are provided including a diisocyanate-functional bioabsorbable polymer. In some embodiments, the diisocyanate-functional bioabsorbable polymer can be combined with a functionalized polyol. The resulting bioabsorbable macromer composition can be employed as an adhesive or sealant for medical/surgical uses. | 2011-03-10 |
20110059062 | USE OF HYDROLYTIC AND OXIDATIVE ENZYMES TO DISSOLVE BIOFILM IN AIRWAY PASSAGES - A composition for removal of biofilm in the airway passage is useful for the treatment of infections such as pneumonia cause by | 2011-03-10 |
20110059063 | Antigen binding proteins that bind PAR-2 - The present invention provides compositions and methods relating to or derived from anti-PAR-2 antibodies. In particular embodiments, the invention provides human antibodies that bind PAR-2, PAR-2-binding fragments and derivatives of such antibodies, and PAR-2-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PAR-2-related disorders or conditions. | 2011-03-10 |
20110059064 | Vm23 and Vm24, two scorpion peptides that block human T-lymphocyte potassium channels (sub-type Kv1.3) w/High Selectivity and Decrease the in vivo DTH-responses in Rats - Potassium channels Kv1.3 are known to be implicated in immunological diseases and graft rejections. Disclosed are peptides capable of blocking with high affinity and specificity potassium channels Kv1.3, their pharmaceutical compositions, and methods for their use to block Kv1.3 potassium channels, to treat various immunological conditions and to diagnostic applications. Methods for their chemical synthesis and correct folding are also disclosed. Exemplary peptides correspond to protein components (Vm23 and Vm24) isolated from the venom of the Mexican scorpion | 2011-03-10 |
20110059065 | FUNCTION AND REGULATION OF ADAMTS-1 - The present invention relates to ADAMTS-1 and uses thereof. The present invention also relates to fragments of ADAMTS-1 and methods of inhibiting cell growth and metastasis. The present invention also provide methods of identifying inhibitors and activators relating to the function of ADAMTS-1. | 2011-03-10 |
20110059066 | PAKs as Modifiers of the CHK Pathway and Methods of Use - Human PAK genes are identified as modulators of the CHK pathway, and thus are therapeutic targets for disorders associated with defective CHK function. Methods for identifying modulators of CHK, comprising screening for agents that modulate the activity of PAK are provided. | 2011-03-10 |
20110059067 | MODULATION OF OLIGONUCLEOTIDE CPG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES - The invention provides methods for modulating the immune response caused by CpG dinucleotide-containing compounds. The methods according to the invention enables both decreasing the immunostimulatory effect for antisense applications, as well as increasing the immunostimulatory effect for immunotherapy applications. | 2011-03-10 |
20110059068 | POLYPEPTIDES INVOLVED IN IMMUNE RESPONSE - Polypeptides which comprise a receptor-ligand pair involved in T-cell activation are disclosed. Nucleic acid molecules encoding the polypeptides, and vectors and host cells for expressing the polypeptides are also disclosed. The polypeptides, or agonists and antagonists thereof, are used to treat T-cell mediated disorders. | 2011-03-10 |
20110059069 | Gapr-1 Methods - Methods of treatment, diagnosis and screening related to GAPR-1 are disclosed. | 2011-03-10 |
20110059070 | Combination therapy for tumoral desease treatment - The invention provides a method of treating cancer by administering to a subject in need thereof, the subject being treated with an anti-cancer antibody therapy, a therapeutically effective amount of a delocalized lipophilic cation (DLC) compound such as MKT-077 which is capable of binding mortalin as an adjuvant for the anti-cancer antibody therapy. Also provided are pharmaceutical compositions and article of manufacturer for treating cancer which comprise the DLC compound as an adjuvant for anti-cancer antibody therapy. | 2011-03-10 |
20110059071 | USE OF CD28-SPECIFIC MONOCLONAL ANTIBODIES FOR PRODUCING A PHARMACEUTICAL COMPOSITION FOR TREATING VIRUS INFECTIONS - The invention relates to the use of monoclonal antibodies which are specific for CD28 and activate the T lymphocytes of several up to all subgroups without the occupation of an antigen receptor of the T lymphocytes and which therefor activate said lymphocytes in an antigen unspecific manner or the invention relates to the use of an analogue thereof for producing a pharmaceutical composition in the form of a preparation or a preparation packet for treating virus infections in humans or lower warm-blooded animals having infected T lymphocytes. The pharmaceutical composition additionally contains a virus inhibitor. The invention also relates to a corresponding pharmaceutical composition and a treatment plan including the pharmaceutical composition. | 2011-03-10 |
20110059072 | METHOD FOR TREATING CANCER USING MONOCLONAL ANTIBODIES - The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcγ receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP). | 2011-03-10 |
20110059073 | METHOD FOR TREATING INFECTIOUS DISEASE USING MONOCLONAL ANTIBODIES - The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcγ receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP). | 2011-03-10 |
20110059074 | Knowledge-Based Proliferation Signatures and Methods of Use - The present invention provides methods and compositions for predicting patient responses to cancer treatment using a proliferation gene signature. These methods can comprise measuring in a biological sample from a patient the levels of gene expression of a group of the genes designated herein. The present invention also provides for microarrays that can detect expression from a group of genes. | 2011-03-10 |
20110059075 | AGLYCOSYLATED IMMUNOGLOBULIN MUTANTS - The present invention is based, in part, on our discovery of immunoglobulins (e.g., immunoglobulin G (IgG)) polypeptides (e.g., murine or human IgG, such as human IgG1) that are aglycosylated yet retain the ability to bind to an Fc receptor, such as an activating Fc receptor (e.g., Fcy RIIA and/or FcyRIIIA). | 2011-03-10 |
20110059076 | HUMAN SERUM ALBUMIN LINKERS AND CONJUGATES THEREOF - Disclosed is a human serum albumin (HSA) linker and HSA linker with binding, diagnostic, and therapeutic agents conjugated thereto. Also disclosed is a conjugate in which the HSA linker is covalently bonded to amino and carboxy terminal binding moieties that are first and second single-chain Fv molecules (scFvs). Exemplified conjugates are useful, e.g., in reducing tumor cell proliferation, e.g., for therapeutic therapeutic applications. Also disclosed are methods and kits for the diagnostic and therapeutic application of an HSA linker conjugate. | 2011-03-10 |
20110059077 | HUMANIZED ANTI-HUMAN ALPHA 9-INTEGRIN ANTIBODY - The present invention provides a humanized anti-human α9 integrin antibody having improved activity and/or property as compared to a donor mouse anti-human α9 integrin antibody, namely, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:11 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:13 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:15 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:9, and a means for the prophylaxis or treatment of various diseases involving human α9 integrin in the pathogenesis, which uses the antibody. | 2011-03-10 |
20110059078 | ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY - The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies. | 2011-03-10 |
20110059079 | Antibody Coformulations - This invention relates to stable formulations of multiple antibodies comprising a plurality of antibodies and an effective amount of a succinate buffer wherein the pH of the formulation is between about 4.5 and about 7.0. | 2011-03-10 |
20110059080 | USE OF AN ANTI-IL6 ANTIBODY TO DECREASE HEPCIDIN IN CANCER PATIENTS - A method of reducing serum hepcidin in a patent having a malignancy or lymphoproliferative disorder by administering an IL-6 neutralizing antibody. | 2011-03-10 |
20110059081 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RECEPTOR TYROSINE KINASE MEDIATED DISEASES OR DISORDERS - The present disclosure provides methods and compositions for treating a disease or disorder in a subject, the method comprising, administering to the subject a therapeutically effective amount of one or more receptor tyrosine kinase inhibitors and a therapeutically effective amount of one or more inhibitors of the dihydrofolate reductase (DHFR) pathway including, for example, methyltransferase inhibitors. | 2011-03-10 |
20110059082 | AGENT FOR TREATING DISEASE - The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 10 mg to 200 mg. | 2011-03-10 |
20110059083 | AGENT FOR TREATING DISEASE - The present invention provides pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject at most every 3 days. | 2011-03-10 |
20110059084 | AGENT FOR TREATING DISEASE - The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 0.2 mg to 30 mg. | 2011-03-10 |
20110059085 | Staphylococcus aureus-specific antibody preparations - A new antibody-based strategy for treating or preventing | 2011-03-10 |
20110059086 | ESPFU NUCLEIC ACIDS AND PROTEINS AND USES THEREOF - Disclosed are EspF | 2011-03-10 |
20110059087 | IL-17 AND IL-23 ANTAGONISTS AND METHODS OF USING THE SAME - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17, IL-23 via it's p19 subunit or both IL-17 and IL-23 (via p19). IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease. | 2011-03-10 |
20110059088 | Protein involved in ovarian cancer - The present invention relates to new uses of CDCP1 in the diagnosis, screening, treatment and prophylaxis of ovarian cancer. The invention also provides compositions comprising CDCP1, including vaccines, antibodies that are immunospecific for CDCP1 and agents which interact with or modulate the expression or activity of CDCP1 or which modulate the expression of the nucleic acid which codes for CDCP1. | 2011-03-10 |
20110059089 | Protein Markers for Cardiovascular Events - The present invention relates to a method for predicting the risk of a subject developing a cardiovascular event comprising detecting at least one biomarker in (a sample of) the cardiovascular system from said subject, wherein said biomarker comprises at least one protein selected from the group consisting of Tumor Necrosis Factor Alpha Precursor; Lysosomal-associated Membrane Protein (1); Interleukin-5 Precursor; Interleukin-6 Precursor; C-C Motif Chemokine (2) Precursor; C-C Motif Chemokine (5) Precursor RANTES; Cathepsin L1 Precursor; Adenylate Kinase (1); Leukotriene B4 Receptor (1); Complement Factor D; Secreted Phosphoprotein (1); Small Inducible Cytokine A17 Precursor; C-X-C Motif Chemokine (10) Precursor; Tumor Necrosis Factor Ligand Superfamily Member (11) (RANKL); C-C Motif Chemokine (18) Precursor; 72 kDa Type IVCollagenase Precursor; Neutrophil Collagenase Precursor; fatty acid binding protein (4); calpain (2), (m/II) large subunit; Macrophage Migration Inhibitory Factor; Cathepsin S Precursor; Interleukin (13) Precursor; and soluble ICAM-1. | 2011-03-10 |
20110059090 | AMINO ACID SEQUENCES DIRECTED AGAINST HER2 AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF CANCERS AND/OR TUMORS - The present invention relates to amino acid sequences and Nanobodies that are directed against Epidermal Growth Factor Receptor 2 (HER2), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. | 2011-03-10 |
20110059091 | INHIBITORS OF ONCOGENIC ISOFORMS AND USES THEREOF - Isoform-binding molecules that specifically bind to one or more isoforms expressed and/or associated with oncogenic phenotypes in a hyperproliferative cell (e.g., a cancerous or tumor cell) are disclosed. The isoform-binding molecules can be used to treat, prevent and/or diagnose cancerous conditions and/or disorders. Methods of using the isoform-binding molecules to selectively detect oncogenic isoforms, to reduce the activity and/or induce the killing of a hyperproliferative cell expressing an oncogenic isoform in vitro, ex vivo or in vivo are also disclosed. Diagnostic and/or screening methods and kits for evaluating the function or expression of an oncogenic isoform are also disclosed. | 2011-03-10 |
20110059092 | ANTIBODIES SPECIFIC OF THE BETA-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS - The present invention relates to a monoclonal antibody which specifically binds to the N-terminal region of Aβ | 2011-03-10 |
20110059093 | USE OF AN ANTI-TAU PS422 ANTIBODY FOR THE TREATMENT OF BRAIN DISEASES - An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy. | 2011-03-10 |
20110059094 | ANTITUMOR EFFECTS OF INSULIN-RESPONSIVE DNA BINDING PROTEIN-1 (IRDBP-1) - Methods of inhibiting growth of tumor cells with a nucleic acid encoding IRDBP-1 or the carboxyl segment thereof are disclosed. Also disclosed are methods for treating tumor with an antibody specific against one of the epitopes in the amino segment of IRDBP-1. In addition, methods of identifying a compound that affects the activity of IRDBP-1 in a cell are disclosed. | 2011-03-10 |
20110059095 | HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN PROTEASE-ACTIVATED RECEPTOR-2 - The present invention provides antibodies that bind to protease-activated receptor-2 (PAR-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PAR-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more PAR-2 biological activities, including the treatment of pain conditions, inflammatory conditions and gastrointestinal conditions. | 2011-03-10 |
20110059096 | Targeting of Notch3 Receptor Function for Cancer Therapy - The present invention involves the use of peptides from Notch3, and antibodies that recognize epitopes represented by those peptides, as anti-cancer agents. Methods of combination therapy using standard anti-cancer protocols in conjunction with Notch3 peptides and antibodies also are provided. | 2011-03-10 |
20110059097 | MFAP4 as a Marker For Regulatory Cells and Anti-Cancer Cells - The present application provides a novel antibody that is specific for MFAP4. The application also provides methods and uses of MFAP4 as a marker for regulatory cells and/or anti-cancer cells. Further, the application provides methods and uses of MFAP4 binding agents for selection and activation of regulatory cells and/or anti-cancer cells. | 2011-03-10 |
20110059098 | Human Anthrax Toxin Neutralizing Monoclonal Antibodies and Methods of Use Thereof - The invention fully humanized monoclonal antibodies that neutralize | 2011-03-10 |